Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
Rhea-AI Summary
Oramed Pharmaceuticals (NASDAQ: ORMP) is set to join the Russell 2000 and Russell 3000 indexes following the 2026 semi-annual reconstitution. Final index membership occurs after U.S. market close on June 26, 2026, and is effective for trading on June 29, 2026.
The indexes, run by FTSE Russell, cover the 4,000 largest U.S. stocks by market cap and are widely used as benchmarks, with about $12.2 trillion in assets tied to Russell U.S. indexes.
Positive
- Inclusion in Russell 2000 and Russell 3000 indexes after 2026 reconstitution
- Membership in Russell 3000 lasts one year, supporting continued index presence
- Exposure to benchmarks used for approximately $12.2 trillion in U.S. assets
Negative
- None.
News Market Reaction – ORMP
In the Jun 17 session, ORMP gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Strategic transaction | Positive | -1.2% | Transfer of POD™ oral drug platform to Lifeward with equity and royalties. |
| Jan 07 | Dividend and payment | Positive | +6.5% | Scilex payment, cumulative returns update, and approval of cash dividend. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed alignment: one positive strategic deal saw a slight decline, while a positive capital return event coincided with a notable gain.
Over recent months Oramed reported two notable events. On Jan 7, 2026, it received payments from Scilex and approved a cash dividend, with a +6.51% 24-hour move. On Jan 13, 2026, it announced a strategic Lifeward transaction involving its POD™ platform, but the stock slipped 1.17%. Against this backdrop of strategic repositioning and capital returns, today’s planned inclusion in the Russell 2000® and Russell 3000® indexes adds an indexation milestone rather than a fundamental change.
Key Terms
russell 2000 financial
russell 3000 financial
russell 1000 financial
ftse russell financial
index funds financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Semi-annual Russell indexes reconstitution captures the 4,000 largest
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a diversified operating company that deploys capital across the biomedical and broader investment landscape, leveraging deep industry relationships, regulatory expertise, and operational experience to build and actively support a diversified portfolio of holdings. For more information, please visit https://oramed.com/.
About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
For more information, visit www.ftserussell.com.
Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, we are using forward-looking statements when we discuss our business strategy; the acquisition, operation, and growth of companies we invest in; clinical development and regulatory initiatives; commercialization activities; capital markets and financing activities; strategic transactions; product development programs; technologies; and potential future opportunities. In addition, historic results of scientific research, clinical trials, investments, strategic transactions or other business activities do not guarantee that future results will be identical or even similar. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to our ability to obtain additional funding, complete strategic transactions, and deploy capital effectively; our ability to identify, acquire, integrate, and successfully operate companies we invest in; our ability to recruit, retain, and oversee qualified management teams at such companies; the success of clinical development, regulatory, commercialization, and business development strategies the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; our ability to obtain additional funding required to conduct our research, development and commercialization activities; and risks related to our investment portfolio, including fluctuations in the value of public and private investments, the performance of portfolio companies, royalty-generating assets and other investment holdings. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inability to identify, complete, or realize anticipated benefits from strategic investments, acquisitions, dispositions, financings or other transactions; concentration risk arising from significant positions in a limited number of investments or industries; changes in technology, market conditions, healthcare industry trends and capital markets; delays or obstacles in clinical development, regulatory review, or strategic initiatives inability to timely develop and introduce new technologies, products, applications or investment opportunities; adverse developments affecting portfolio companies, including operational, financial, regulatory, clinical, or commercial setbacks; unforeseen scientific difficulties that may develop with our process; loss of market share and pressure on pricing resulting from competition; risks relating to intellectual property protection and enforcement; and adverse developments affecting portfolio companies, investments, licensing arrangements, royalty interests, or strategic counterparties;, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
Company Contact
+1-844-9-ORAMED
estee@oramed.com
Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oramed-pharmaceuticals-to-join-russell-2000-and-russell-3000-indexes-302803049.html
SOURCE Oramed Pharmaceuticals Inc.